Pharma/biotech companies are increasingly looking to access large-scale data sets to fill gaps in their computational biology capabilities. Be prepared for the investment.
- How CGT Developers Should Think About Manufacturing Models, Hybrid Strategies, And Scale
- Enhancing Gene And Cell Therapies With Circular RNA-Based Gene Expression
- FDA Explains How To Respond To Form 483 Observations In New Draft Guidance
- Organizing Digital Systems Around Novel Modalities
- Achieving Annex 1 Compliance In Sterile Manufacturing, Part 1: Common Compliance Failures
- Hormuz Deal Brings Cautious Relief To Pharma Packaging Supply Chains
- PUPSIT In Cell & Gene Therapy: Risk Reduction Or Operational Complexity?
- Is Your AI Model Trustworthy And Credible In GMP Processes?
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![GettyImages-2192786673 antibodies]( "Integrated Upstream And Downstream Strategies For Robust Manufacturing")
Integrated Upstream And Downstream Strategies For Robust ManufacturingProcess robust mAb production requires understanding scale dependent cell environments, leveraging predictive models, and pursuing data driven control to minimize variability and optimize quality.
-
![GettyImages-1457289257 patient]( "Quantitative ROI With DCTs")
Quantitative ROI With DCTsThrough dedicated staffing, operational oversight, and collaboration with site teams, see how we were able to transform a struggling cardiology study into a revitalized recruitment effort.
-
![I02_michigan injmolding floor-REVISED-a (3)]( "Implementing Medium And High-Volume Drug Handling And Packaging Programs")
Implementing Medium And High-Volume Drug Handling And Packaging ProgramsSimplify the complexity of combination product development by partnering for integrated support across device design, industrialization, manufacturing, and final product assembly.
-
![GettyImages-687868860-Test tubes_Vial_Lab]( "Control Strategies And Method Development For Nitrosamines In APIs And Drug Products")
Control Strategies And Method Development For Nitrosamines In APIs And Drug ProductsExplore regulatory insights, analytical strategies, and real-world case studies for effective nitrosamine control in APIs and drug products.
-
![GettyImages-1500981700 cell culture]( "Automated DNA Clean-Up Using Magnetic Bead-Based Methods")
Automated DNA Clean-Up Using Magnetic Bead-Based MethodsDiscover how to improve DNA clean‑up through a precise magnetic bead–based workflow, as well as how optimized liquid handling enhances yield, purity, and reproducibility for higher confidence in results.
-
![GettyImages-627023398 clinical lab]( "AAV Viral Titering Using Nanoplate-Based Digital PCR")
AAV Viral Titering Using Nanoplate-Based Digital PCRExamine how nanoplate-based digital PCR streamlines AAV titering, providing faster results and greater accuracy, advancing gene therapy development from the lab to the clinic.
-
![GettyImages-1590576166 cells, research, lab, assay]( "Stability Of Supplemented PRIME-XV T Cell CDM At Room Temperature")
Stability Of Supplemented PRIME-XV T Cell CDM At Room TemperatureGain insight into how a supplemented medium stored at room temperature for up to 72 hours maintained T cell expansion performance, showing consistent viability and marker expression.
-
![cell-therapy-GettyImages-1494029118]( "Expanding The Capabilities Of Targeted Integration")
Expanding The Capabilities Of Targeted IntegrationSee the demonstration of precise, site‑specific integration of a 50 kb multi‑gene construct into human iPSCs, overcoming size limits of traditional genome‑engineering approaches.
-
![Picture 2409-123 (1)]( "Seamless Workflow For Environmental Monitoring")
Seamless Workflow For Environmental MonitoringLearn how connected sampling tools and compliant monitoring software improve data integrity and streamline compressed gas testing workflows, offering a path to reliable environmental monitoring.
-
![GettyImages-1493793609 chromatography]( "Alternative Two-Step Mixed-Mode Approach To A mAb Purification Process")
Alternative Two-Step Mixed-Mode Approach To A mAb Purification ProcessTwo post–Protein A capture two-step mAb processes were developed and compared to an archetypical three-step mAb purification process using two IEX steps after Protein A capture.
NEWSLETTER ARCHIVE
- 07.02.26 -- New Podcast Episodes: A Midyear Look At Life Sciences, Derisking CNS Drug Development, In Vivo Gene Editing
- 07.02.26 -- Why Improving Drug Delivery Remains A Major Opportunity In Oncology
- 07.01.26 -- In Vivo Gene Editing Is Moving From Promise To Proof
- 06.30.26 -- Cell Therapy Without The Cells: Building A Therapeutic Secretome
- 06.30.26 -- Better IDS Workflows Start Here
- How CGT Developers Should Think About Manufacturing Models, Hybrid Strategies, And Scale
- In Vivo Gene Editing Is Moving From Promise To Proof
- Driving Gene Therapy Beyond Rare Disease Will Define The Next Era Of CGT
- CGT Manufacturing Shifts From Capacity To Strategy
- Dr. Peter Marks On Why Gene Therapy May Need A New Regulatory Playbook
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections
